Priti Gros1, Victoria P Mery2, Anne-Louise Lafontaine3, Ann Robinson4, Andrea Benedetti5,6, R John Kimoff4, Marta Kaminska4,6. 1. Respiratory Division & Sleep Laboratory, McGill University Health Centre, 1001 Decarie Blvd, Montreal, Quebec, H4A 3J1, Canada. priti.gros@mail.mcgill.ca. 2. Neurology Department, Clinica Alemana de Santiago, Santiago, Chile. 3. Montreal Neurological Hospital, McGill University Health Centre, Montreal, QC, Canada. 4. Respiratory Division & Sleep Laboratory, McGill University Health Centre, 1001 Decarie Blvd, Montreal, Quebec, H4A 3J1, Canada. 5. Department of Medicine and Department of Epidemiology, Biostatistics & Occupational Health, McGill University Health Centre, Montreal, QC, Canada. 6. Respiratory & Epidemiology and Clinical Research Unit, McGill University Health Centre, Montreal, QC, Canada.
Abstract
PURPOSE:Obstructive sleep apnea (OSA) results from upper airway (UA) obstruction. In Parkinson's disease (PD), levodopa improves UA obstruction during wakefulness. We hypothesized that bedtime controlled-release levodopa (Sinemet CR) is associated with less severe OSA (lower apnea-hypopnea index [AHI]) in PD patients. METHODS:Idiopathic PD subjects underwentnocturnal polysomnography (PSG) and were divided into those taking bedtime Sinemet CR (SinCR+) and those not taking Sinemet CR (SinCR-). Outcomes were compared between groups for PSG recordings analyzed in whole and split at their mid-point with each half analyzed separately, using linear regression. RESULTS:Fifty-seven subjects were studied, eight SinCR+, and 49 SinCR-. They were 65 % male, aged64.4 ± 10.3 years (mean ± SD), with body mass index 27.26 ± 3.98 kg/m(2). The whole night AHI was 15.6 ± 13.3 and 29.1 ± 20.8 in SinCR+ and SinCR-, respectively (p = 0.07 unadjusted, p = 0.11 adjusted for confounders). A similar trend was observed in the first half of the night. In the second half, the SinCR+ group had significantly lower AHI (beta = -18.8; p = 0.01 adjusted) and respiratory arousal index (beta = -14.2; p = 0.02 adjusted) than the SinCR- group. CONCLUSIONS: Bedtime Sinemet CR appears to reduce OSA in PD patients. There were no significant differences between groups in the first half of the night likely because of residual effects of short-acting levodopa in both groups, while Sinemet CR had residual effect in the second half. These results possibly provide an alternative to help manage OSA and improve sleep quality in PD patients.
RCT Entities:
PURPOSE: Obstructive sleep apnea (OSA) results from upper airway (UA) obstruction. In Parkinson's disease (PD), levodopa improves UA obstruction during wakefulness. We hypothesized that bedtime controlled-release levodopa (Sinemet CR) is associated with less severe OSA (lower apnea-hypopnea index [AHI]) in PDpatients. METHODS:Idiopathic PD subjects underwent nocturnal polysomnography (PSG) and were divided into those taking bedtime Sinemet CR (SinCR+) and those not taking Sinemet CR (SinCR-). Outcomes were compared between groups for PSG recordings analyzed in whole and split at their mid-point with each half analyzed separately, using linear regression. RESULTS: Fifty-seven subjects were studied, eight SinCR+, and 49 SinCR-. They were 65 % male, aged 64.4 ± 10.3 years (mean ± SD), with body mass index 27.26 ± 3.98 kg/m(2). The whole night AHI was 15.6 ± 13.3 and 29.1 ± 20.8 in SinCR+ and SinCR-, respectively (p = 0.07 unadjusted, p = 0.11 adjusted for confounders). A similar trend was observed in the first half of the night. In the second half, the SinCR+ group had significantly lower AHI (beta = -18.8; p = 0.01 adjusted) and respiratory arousal index (beta = -14.2; p = 0.02 adjusted) than the SinCR- group. CONCLUSIONS: Bedtime Sinemet CR appears to reduce OSA in PDpatients. There were no significant differences between groups in the first half of the night likely because of residual effects of short-acting levodopa in both groups, while Sinemet CR had residual effect in the second half. These results possibly provide an alternative to help manage OSA and improve sleep quality in PDpatients.
Authors: Ariel B Neikrug; Lianqi Liu; Julie A Avanzino; Jeanne E Maglione; Loki Natarajan; Lenette Bradley; Alex Maugeri; Jody Corey-Bloom; Barton W Palmer; Jose S Loredo; Sonia Ancoli-Israel Journal: Sleep Date: 2014-01-01 Impact factor: 5.849
Authors: Richard P Allen; Brendan J Burchell; Ben MacDonald; Wayne A Hening; Christopher J Earley Journal: Sleep Med Date: 2009-02-04 Impact factor: 3.492
Authors: David P Breen; Romina Vuono; Upekshani Nawarathna; Kate Fisher; John M Shneerson; Akhilesh B Reddy; Roger A Barker Journal: JAMA Neurol Date: 2014-05 Impact factor: 18.302
Authors: Marta Kaminska; Victoria P Mery; Anne-Louise Lafontaine; Ann Robinson; Andrea Benedetti; Priti Gros; R John Kimoff Journal: J Clin Sleep Med Date: 2018-05-15 Impact factor: 4.062